[Form 4] LifeMD, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LifeMD director Roberto Simon received 22,365 restricted stock units on 10/02/2025, increasing his beneficial ownership to 183,175 shares. The Form 4 shows the units were granted at a $0 price and are recorded as non‑derivative common stock awards.

The filing specifies the granted awards are restricted stock units that vest on June 1, 2026, so the director will not hold transferable shares until vesting occurs. The Form 4 is an individual filing by a company director and shows no cash purchase or sale associated with this transaction.

Positive

• 22,365 RSUs granted increases director alignment with shareholders
• Beneficial ownership rose to 183,175 shares, strengthening insider stake
• Grant vests on June 1, 2026, indicating a retention incentive

Negative

• Granted at $0 reflects compensation rather than a purchase, potentially dilutive when vested
• Shares not immediately vested, so ownership increase is not presently transferable

Insights

Corporate Governance Analyst

Director grant boosts ownership and aligns incentives ahead of vesting.

The 22,365 restricted stock units increase the director's stake to 183,175 shares, which is a straightforward equity compensation event that ties the director's compensation to share performance through vesting on June 1, 2026. Such grants are commonly used to retain executives and directors and to align long‑term interests with shareholders.

Key dependencies include the vesting date and any forfeiture conditions; the economic and voting rights normally attach only after conversion to shares at vesting. Monitor the June 1, 2026 vesting milestone for changes in ownership and any subsequent Form 5/Form 4 that records actual share receipts or dispositions within the following reporting periods.

Compensation & Dilution Specialist

Granted at $0 shows a compensation award rather than a market purchase.

The transaction price of $0 indicates these are equity awards (RSUs) rather than purchases, increasing potential outstanding shares only when RSUs convert to common stock at vesting. The filing does not show an immediate cash transaction or sale, so no realized proceeds occurred on the reported date.

Material near‑term items to watch include any filings showing the RSUs converting to shares on June 1, 2026 and company disclosures about share reserve usage which could indicate dilution timing and magnitude relative to total shares outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Roberto

(Last) (First) (Middle)

C/O LIFEMD, INC.

236 FIFTH AVENUE, 4TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		A		22,365(1)	A	$0	183,175	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units that vest on June 1, 2026.

	/s/ Roberto Simon	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did LifeMD director Roberto Simon report on Form 4 (LFMD)?

The Form 4 reports a grant of 22,365 restricted stock units on 10/02/2025, bringing his beneficial ownership to 183,175 shares.

Do the reported RSUs for LFMD have a purchase price?

No; the Form 4 shows a transaction price of $0, indicating these are compensation awards (RSUs), not purchases.

When do Roberto Simon's RSUs vest according to the filing?

The filing states the restricted stock units vest on June 1, 2026.

Does the Form 4 show any sale of shares by Roberto Simon (LFMD)?

No. The filing shows an acquisition (A) of RSUs and does not report any dispositions or sales on the reported date.

Is this Form 4 filed individually or jointly?

The Form 4 is filed by one reporting person; the box for an individual filing is checked.